Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Theravance Biopharma Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -32.29%, while the net margin is 18.08%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TBPH converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TBPH competes directly with industry leaders such as GHRS and SPRY. With a market capitalization of $975.95M, it holds a significant position in the sector. When comparing efficiency, TBPH's gross margin of 100.00% stands against GHRS's N/A and SPRY's 74.80%. Such benchmarking helps identify whether Theravance Biopharma Inc is trading at a premium or discount relative to its financial performance.
